Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6021635 | Neurobiology of Disease | 2015 | 13 Pages |
Abstract
Aside from the lack of positive effect of m266 and 1C22 on cognition, a substantial number of deaths occurred in m266- and 1C22-immunized J20 mice. These fatalities were specific to anti-Aβ antibodies and to the J20 mouse line since treatment of wild type or PDAPP mice with these antibodies did not cause any deaths. These and other recent results indicate that J20 mice are particularly susceptible to targeting of the APP/Aβ/tau axis. Notwithstanding the specificity of fatalities for J20 mice, it is worrying that the murine precursor (m266) of a lead experimental therapeutic, Solanezumab, did not engage with putatively pathogenic Aβ oligomers.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Alexandra J. Mably, Wen Liu, Jessica M. Mc Donald, Jean-Cosme Dodart, Frédérique Bard, Cynthia A. Lemere, Brian O'Nuallain, Dominic M. Walsh,